Satellos Bioscience to Present Key Clinical and Preclinical Data at 2026 MDA Conference

summarizeSummary

Satellos Bioscience announced it will present data from its completed Phase 1a/b study of SAT-3247 and new preclinical data at the upcoming Muscular Dystrophy Association Clinical & Scientific Conference.

check_boxKey Events

• Upcoming Conference Presentations

  Satellos Bioscience will deliver two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference from March 8-11 in Orlando, Florida.

• Oral Presentation Highlights

  Oral presentations will feature data from the completed Phase 1a/b study of SAT-3247 in healthy volunteers and adult Duchenne muscular dystrophy (DMD) patients, alongside new preclinical data evaluating SAT-3247 in a mouse model of facioscapulohumeral muscular dystrophy (FSHD).

• Poster Presentation Details

  Poster sessions will include further details on the Phase 1a/b study, an update on the TRAILHEAD Phase 2 study evaluating SAT-3247 in adults with DMD, and research on regenerative potential in DMD patients.

auto_awesomeAnalysis

Satellos Bioscience's announcement of multiple oral and poster presentations at the upcoming Muscular Dystrophy Association Clinical & Scientific Conference is an important update for investors. For a clinical-stage biotechnology company, presenting data from completed Phase 1a/b studies, new preclinical findings, and updates on ongoing Phase 2 trials at a major scientific conference signifies active pipeline progression and engagement with the scientific community. This event provides a platform to showcase the potential of SAT-3247 for Duchenne and other degenerative muscle diseases, which could generate investor interest, especially as the company's stock is currently trading near its 52-week low.